BOV.F Apyx Medical Corporation
- Market cap
- EUR 108M
- P/E
- -
- P/B
- 12.47x
- ROE
- -98.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BOV.F undervalued?
Graham numberThe Graham number of Apyx Medical Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apyx Medical Corporation fundamental analysis
No fundamental analysis for Apyx Medical Corporation yet.
Apyx Medical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a…
Full company profileApyx Medical Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apyx Medical Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.6M | 38.9M | 16.7M | 28.2M | 27.7M | 48.5M | 44.5M | 52.3M | 48.1M | 52.8M | 53.9M |
| Gross Profit | 17.9M | 19.8M | 10.8M | 19.1M | 17.5M | 33.6M | 29.1M | 33.8M | 29.4M | 33.0M | 34.4M |
| Operating Income | -3.79M | -3.74M | -12.9M | -20.9M | -20.1M | -14.4M | -23.6M | -20.0M | -18.8M | -6.45M | -4.38M |
| EBITDA | - | -4.39M | -12.5M | -19.1M | -18.5M | -14.8M | -22.9M | -18.1M | -16.8M | -4.59M | -2.50M |
| Net Income | -3.95M | -5.06M | 64.0M | -19.7M | -11.9M | -15.2M | -23.2M | -18.7M | -23.5M | -11.2M | -9.51M |
| EPS | - | -0.15 | 1.90 | -0.58 | -0.35 | -0.44 | -0.67 | -0.54 | -0.62 | -0.27 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 35.1M | 31.0M | 95.6M | 84.7M | 74.1M | 68.7M | 51.8M | 79.2M | 64.8M | 66.8M | 61.7M |
| Total Liabilities | 8.89M | 8.96M | 7.84M | 13.5M | 10.3M | 14.7M | 14.0M | 52.3M | 50.5M | 52.0M | 51.6M |
| Shareholders' Equity | 26.2M | 22.0M | 87.8M | 71.3M | 63.7M | 53.7M | 37.6M | 26.7M | 14.2M | 14.5M | 9.63M |
| Cash & Short-term Investments | 14.5M | 9.95M | 16.5M | 58.8M | 41.9M | 30.9M | 10.2M | 43.7M | 31.7M | 31.7M | 25.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.84M | -3.70M | -20.9M | -18.5M | -16.1M | -10.4M | -20.3M | -5.25M | -18.0M | -8.00M | -7.59M |
| Capital Expenditure | 286K | 624K | 363K | 1.30M | 581K | 723K | 1.01M | 533K | 722K | 1.11M | 521K |
| Free Cash Flow | - | -4.33M | -21.4M | -19.8M | -16.6M | -11.2M | -21.3M | -5.78M | -18.8M | -9.12M | -8.12M |
| Ratios | |||||||||||
| ROE | -15.1% | -23.0% | 72.9% | -27.7% | -18.7% | -28.3% | -61.7% | -70.1% | -165.1% | -77.1% | -98.8% |
| ROA | -11.3% | -16.3% | 66.9% | -23.3% | -16.1% | -22.1% | -44.8% | -23.6% | -36.2% | -16.8% | -15.4% |
| Net Profit Margin | -10.8% | -13.0% | 383.6% | -69.8% | -42.9% | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% | -17.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Apyx Medical Corporation dividends
Apyx Medical Corporation has not paid dividends in the last 9 fiscal years.
Who owns Apyx Medical Corporation
- Insiders 13.55%
- Institutions 53.38%
- Public & others 33.07%
- Shares outstanding 42.1M
- Free float 30.5M
Apyx Medical Corporation company profile
- Company name
- Apyx Medical Corporation
- Ticker
- BOV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 205
- Fiscal year end
- December
- Address
- 5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004
- Phone
- 727 384 2323
- Website
- apyxmedical.com
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Apyx Medical Corporation management
5- Mr. Charles D. Goodwin IIPresident, CEO & Director · born 1966
- Mr. Matthew C. Hill CPACFO, Treasurer & Secretary · born 1969
- Mr. Shawn D. RomanChief Operating Officer · born 1972
- Mr. Moshe CitronowiczSenior Vice President · born 1953
- Ms. Dolores CataniaChief of Confidence